Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Iversen

Showing results (141-150 of 156) with videos related to

Pageof 16
Sort By:
European Urology Focus|July 30, 2017
The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical ProstatectomyMartin Andreas Røder, Kasper Drimer Berg, Mathias Dyrberg Loft, et al.
European Urology|February 18, 2015
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up ResultsBertrand Tombal, Michael Borre, Per Rathenborg, et al.
Urology|May 12, 2004
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer programPeter Iversen, Manfred P Wirth, William A See, et al.
The Journal of Urology|November 12, 2003
Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatmentPeter R Carroll, David A Benaron, George Blackledge, et al.
European Urology|March 24, 2016
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerChristopher P Evans, Celestia S Higano, Thomas Keane, et al.
The Journal of Urology|July 20, 2002
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer programWilliam A See, Manfred P Wirth, David G McLeod, et al.
European Urology|August 2, 2016
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyTomasz M Beer, Andrew J Armstrong, Dana Rathkopf, et al.
The Journal of Urology|November 13, 2004
Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and TreatmentPeter R Carroll, June M L Chan, Anthony V D'Amico, et al.
The New England Journal of Medicine|June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapyTomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
BMJ (Clinical Research Ed.)|January 12, 2018
Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohortsTyler M Seibert, Chun Chieh Fan, Yunpeng Wang, et al.
Pageof 16

Showing results (141-150 of 156) with videos related to

Sort By:
Pageof 16
European Urology Focus|July 30, 2017
The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical ProstatectomyMartin Andreas Røder, Kasper Drimer Berg, Mathias Dyrberg Loft, et al.
European Urology|February 18, 2015
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up ResultsBertrand Tombal, Michael Borre, Per Rathenborg, et al.
Urology|May 12, 2004
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer programPeter Iversen, Manfred P Wirth, William A See, et al.
The Journal of Urology|November 12, 2003
Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatmentPeter R Carroll, David A Benaron, George Blackledge, et al.
European Urology|March 24, 2016
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerChristopher P Evans, Celestia S Higano, Thomas Keane, et al.
The Journal of Urology|July 20, 2002
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer programWilliam A See, Manfred P Wirth, David G McLeod, et al.
European Urology|August 2, 2016
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyTomasz M Beer, Andrew J Armstrong, Dana Rathkopf, et al.
The Journal of Urology|November 13, 2004
Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and TreatmentPeter R Carroll, June M L Chan, Anthony V D'Amico, et al.
The New England Journal of Medicine|June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapyTomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
BMJ (Clinical Research Ed.)|January 12, 2018
Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohortsTyler M Seibert, Chun Chieh Fan, Yunpeng Wang, et al.
Pageof 16